Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Nozomu Wada is active.

Publication


Featured researches published by Nozomu Wada.


Hepatology Research | 2014

Involvement of platelets in extrahepatic metastasis of hepatocellular carcinoma

Yuki Morimoto; Kazuhiro Nouso; Nozomu Wada; Yasuto Takeuchi; Hideaki Kinugasa; Koji Miyahara; Tetsuya Yasunaka; Kenji Kuwaki; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

Recently, a relationship between platelets and cancer metastasis has been reported. The aim of this study is to elucidate the risk factors for extrahepatic metastasis (EHM), with emphasis on association with platelets in patients, with hepatocellular carcinoma (HCC).


American Journal of Roentgenology | 2011

Percutaneous Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma in the Caudate Lobe

Kazuya Kariyama; Kazuhiro Nouso; Akiko Wakuta; Masayuki Kishida; Mamoru Nishimura; Nozomu Wada; Toshihiro Higashi

OBJECTIVE This study aimed to evaluate the efficacy and safety of percutaneous radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC) in the caudate lobe, where RFA is considered to be difficult. MATERIALS AND METHODS Of a total of 810 patients treated by ultrasound-guided radiotherapy between July 2002 and May 2010, medical records of 50 consecutive patients with HCC in the caudate lobe were reviewed in this retrospective study. Twenty-two tumors were found to be in the paracaval portion and 28 in the Spiegel lobe. We retrospectively reviewed the procedures, treatment effect, and complications. RESULTS For all paracaval tumors and eight Spiegel lobe tumors, we used the intercostal approach, and for the remaining Spiegel tumors (n = 20) we used the pass-the-left approach. We found that all tumors were successfully treated, and the local recurrence rate after 2 years was 12%. Cases of mortality or major complications after RFA were absent. CONCLUSION RFA appears to be an effective treatment modality for HCC in the caudate lobe.


Oncology | 2011

Radiofrequency Ablation for the Treatment of Hepatocellular Carcinoma with Decompensated Cirrhosis

Akiko Wakuta; Kazuhiro Nouso; Kazuya Kariyama; Mamoru Nishimura; Masayuki Kishida; Nozomu Wada; Takaaki Mizushima; Toshihiro Higashi; Mitsune Tanimoto

Background: Radiofrequency ablation (RFA) is used to treat early-stage hepatocellular carcinoma (HCC), but is sometimes avoided in patients with decompensated liver cirrhosis because of the possible side effect of deterioration of liver function. Aims: In this study, we report the safety and effects of RFA for treating HCC patients with Child-Pugh B/C liver cirrhosis. Methods: Sixty-six consecutive HCC patients with Child-Pugh B/C cirrhosis, who were treated by RFA, were enrolled in this study. We analyzed patient outcomes, the complications of RFA, and changes in liver function and tumor markers. Results: Fifty-six patients were classified as Child-Pugh class B, and 10 were classified as class C. The overall survival rates in patients with Child-Pugh B and C cirrhosis were 82 and 83% at 1 year and 47 and 31% at 3 years, respectively. Serum total bilirubin (T.Bil), albumin, prothrombin time, ascites, and encephalopathy were unchanged at 1, 3, and 6 months after RFA in patients with Child-Pugh B cirrhosis; however, serum T.Bil levels increased significantly at 6 months after RFA in 6/10 (60%) patients with Child-Pugh C cirrhosis. Hemothorax and rupture of esophageal varices were observed in 2 patients; however, there were no complications related to poor liver function. Conclusion: RFA is a useful modality for treating HCC in patients with poor liver function such as Child-Pugh B and C, but careful monitoring after RFA must be needed.


Journal of Gastroenterology and Hepatology | 2015

Use of non-invasive serum glycan markers to distinguish non-alcoholic steatohepatitis from simple steatosis

Yasushi Yamasaki; Kazuhiro Nouso; Koji Miyahara; Nozomu Wada; Chihiro Dohi; Yuki Morimoto; Hideaki Kinugasa; Yasuto Takeuchi; Tetsuya Yasunaka; Kenji Kuwaki; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Yoshiaki Iwasaki; Maho Amano; Shin-Ichiro Nishimura; Kazuhide Yamamoto

Serum glycans have been reported to be promising diagnostic markers for many inflammatory diseases and cancers. The aims of this study were to investigate whole glycan expression in patients with non‐alcoholic fatty liver diseases and to evaluate the potential use of glycan profiles as new clinical biomarkers to distinguish non‐alcoholic steatohepatitis (NASH) from simple steatosis (SS).


Scientific Reports | 2015

Beneficial impact of Gpnmb and its significance as a biomarker in nonalcoholic steatohepatitis

Akihiro Katayama; Atsuko Nakatsuka; Jun Eguchi; Kazutoshi Murakami; Sanae Teshigawara; Motoko Kanzaki; Tomokazu Nunoue; Kazuyuki Hida; Nozomu Wada; Tetsuya Yasunaka; Fusao Ikeda; Akinobu Takaki; Kazuhide Yamamoto; Hiroshi Kiyonari; Hirofumi Makino; Jun Wada

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. Gpnmb is classified as a type 1 membrane protein and its soluble form is secreted by ADAM10-mediated cleavage. Gpnmb mRNA was found in the Kupffer cells and white adipose tissues (WATs) and its upregulation in obesity was recently found. Here, we generated aP2 promoter-driven Gpnmb transgenic (Tg) mice and the overexpression of Gpnmb ameliorated the fat accumulation and fibrosis of the liver in diet-induced obesity model. Soluble form of Gpnmb in sera was elevated in Gpnmb Tg mice and Gpnmb concentrated in hepatic macrophages and stellate cells interacted with calnexin, which resulted in the reduction of oxidative stress. In the patients with non-alcoholic steatohepatitis, serum soluble GPNMB concentrations were higher compared with the patients with simple steatosis. The GPNMB is a promising biomarker and therapeutic target for the development and progression of NAFLD in obesity.


Hepatology Research | 2015

Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma

Koji Miyahara; Kazuhiro Nouso; Chihiro Dohi; Yuki Morimoto; Hideaki Kinugasa; Nozomu Wada; Yasuto Takeuchi; Kenji Kuwaki; Hideki Onishi; Fusao Ikeda; Yasuhiro Miyake; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Maho Amano; Shin-Ichiro Nishimura; Kazuhide Yamamoto

Most of the modification of N‐glycosylation reported in cancers including hepatocellular carcinoma (HCC) were based on the examinations of a small number of patients or particular proteins. The aim of this study is to reveal changes in whole serum N‐glycan profiles systematically during the process of hepatocarcinogenesis and to elucidate their clinical application.


Acta Medica Okayama | 2015

Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location.

Junichi Toshimori; Kazuhiro Nouso; Shinichiro Nakamura; Nozomu Wada; Yuki Morimoto; Yasuto Takeuchi; Tetsuya Yasunaka; Kenji Kuwaki; Hideki Ohnishi; Fusao Ikeda; Hidenori Shiraha; Akinobu Takaki; Kazuhide Yamamoto

We conducted a retrospective cohort study to investigate the predisposing factors for local recurrence and complications after percutaneous radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC). HCC patients (n=397) consecutively treated with RFA (256 males, 141 females, median age 69 years) were enrolled. In these patients, 1,455 nodules (median size 17mm) were ablated. Predisposing factors for overall recurrence and local recurrence in the context of tumor location and complications were examined. Local recurrence was observed for 113 of the 1,455 nodules. The 1-, 3- and 5-year local recurrence rates were 2.2%, 7.4% and 9.5%, respectively. A multivariate Cox proportional hazard analysis revealed that large tumor size (>2cm), tumor location (adjacent to the major portal branch or hepatic vein), and small ablated margin (<3mm) were independent predisposing factors for local recurrence after RFA (HR=1.70-2.81). Tumor location (adjacent to the major portal branch, hepatic vein, or diaphragm) was also revealed as a risk factor for liver damage due to RFA. HCC adjacent to the major portal vein or hepatic vein was associated with a higher risk for local recurrence and for complications;therefore, special precautions are necessary when applying RFA to HCC near vessels even when the tumors are located at an easy-to-puncture site.


Hepatology Research | 2016

Potential of alpha‐fetoprotein as a prognostic marker after curative radiofrequency ablation of hepatocellular carcinoma

Chihiro Dohi; Kazuhiro Nouso; Koji Miyahara; Yuki Morimoto; Nozomu Wada; Hideaki Kinugasa; Yasuto Takeuchi; Kenji Kuwaki; Hideki Onishi; Fusao Ikeda; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Hiroyuki Okada

Recurrence of hepatocellular carcinoma (HCC) is observed frequently, even after curative treatments. The aim of this study is to elucidate the risk factors for recurrence of HCC after radiofrequency ablation (RFA), focusing on the carcinogenic potential of the liver assessed by α‐fetoprotein (AFP).


Internal Medicine | 2017

The Serum Oxidative/Anti-oxidative Stress Balance Becomes Dysregulated in Patients with Non-alcoholic Steatohepatitis Associated with Hepatocellular Carcinoma

Yasuyuki Shimomura; Akinobu Takaki; Nozomu Wada; Tetsuya Yasunaka; Fusao Ikeda; Takayuki Maruyama; Naofumi Tamaki; Daisuke Uchida; Hideki Onishi; Kenji Kuwaki; Shinichiro Nakamura; Kazuhiro Nouso; Yasuhiro Miyake; Kazuko Koike; Takaaki Tomofuji; Manabu Morita; Kazuhide Yamamoto; Hiroyuki Okada

Objective Oxidative stress is associated with the progression of chronic liver disease. Non-alcoholic fatty liver disease (NAFLD) is also an oxidative stress-related disease. However, the oxidative/anti-oxidative balance has not been fully characterized in NAFLD. The objective of the present study was to investigate the balance between oxidative stress and the anti-oxidative activity in NAFLD, including non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC). Patients We recruited 69 patients with histologically proven NAFLD without HCC (NAFLD; n=58), and with NASH-related HCC (NASH-HCC; n=11). The 58 NAFLD patients included patients with non-alcoholic fatty liver (NAFL; n=14) and NASH (n=44). Methods The serum levels of reactive oxygen metabolites (ROM) and anti-oxidative markers (OXY) were determined and then used to calculate the oxidative index. The correlations among such factors as ROM, OXY, oxidative index, and clinical characteristics were investigated. Results In NAFLD, ROM positively correlated with the body mass index (BMI), hemoglobin A1c (HbA1c), C-reactive protein (CRP), and the histological grade or inflammatory scores, while only high HbA1c and CRP levels were significant factors that correlated with a higher ROM according to a multivariate analysis. OXY positively correlated with the platelet counts, albumin, and creatinine levels, while negatively correlating with age. However, it improved after treatment intervention. The oxidative index positively correlated with BMI, CRP, and HbA1c. The NASH-HCC patients exhibited a lower OXY than the NASH patients, probably due to the effects of aging. Conclusion Oxidative stress correlated with the levels of NASH activity markers, while the anti-oxidative function was preserved in younger patients as well as in patients with a well-preserved liver function. The NASH-HCC patients tended to be older and exhibited a diminished anti-oxidative function.


Scientific Reports | 2016

Insufficiency of phosphatidylethanolamine N-methyltransferase is risk for lean non-alcoholic steatohepatitis.

Atsuko Nakatsuka; Makoto Matsuyama; Satoshi Yamaguchi; Akihiro Katayama; Jun Eguchi; Kazutoshi Murakami; Sanae Teshigawara; Daisuke Ogawa; Nozomu Wada; Tetsuya Yasunaka; Fusao Ikeda; Akinobu Takaki; Eijiro Watanabe; Jun Wada

Although obesity is undoubtedly major risk for non-alcoholic steatohepatitis (NASH), the presence of lean NASH patients with normal body mass index has been recognized. Here, we report that the insufficiency of phosphatidylethanolamine N-methyltransferase (PEMT) is a risk for the lean NASH. The Pemt−/− mice fed high fat-high sucrose (HFHS) diet were protected from diet-induced obesity and diabetes, while they demonstrated prominent steatohepatitis and developed multiple liver tumors. Pemt exerted inhibitory effects on p53-driven transcription by forming the complex with clathrin heavy chain and p53, and Pemt−/− mice fed HFHS diet demonstrated prominent apoptosis of hepatocytes. Furthermore, hypermethylation and suppressed mRNA expression of F-box protein 31 and hepatocyte nuclear factor 4α resulted in the prominent activation of cyclin D1. PEMT mRNA expression in liver tissues of NASH patients was significantly lower than those with simple steatosis and we postulated the distinct clinical entity of lean NASH with insufficiency of PEMT activities.

Collaboration


Dive into the Nozomu Wada's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge